Adam G Presser
Overview
Explore the profile of Adam G Presser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venkadakrishnan V, Presser A, Singh R, Booker M, Traphagen N, Weng K, et al.
Nat Commun
. 2024 Aug;
15(1):6779.
PMID: 39117665
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration-resistant prostate cancers and implicated as a driver of disease progression...
2.
Venkadakrishnan V, Presser A, Singh R, Booker M, Traphagen N, Weng K, et al.
Res Sq
. 2024 Feb;
PMID: 38405800
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration-resistant prostate cancers and implicated as a driver of disease progression...
3.
Stover E, Baco M, Cohen O, Li Y, Christie E, Bagul M, et al.
Mol Cancer Res
. 2019 Aug;
17(11):2281-2293.
PMID: 31462500
High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy, but most patients relapse with chemotherapy-resistant disease. To systematically identify genes modulating chemotherapy...
4.
Spetz J, Presser A, Sarosiek K
Int Rev Cell Mol Biol
. 2019 Jan;
342:27-71.
PMID: 30635093
Cell death plays two major complementary roles in T cell biology: mediating the removal of cells that are targeted by T cells and the removal of T cells themselves. T...